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Preparation and immunogenicity of gold glyco-nanoparticles as anti-pneumococcal 
8 
9 vaccine model 
10 
11 
12 
13 
ABSTRACT 
14 
15 Background: Nanotechnology-based fully synthetic carbohydrate vaccines are promising 
16 
17 alternatives to classic polysaccharide/protein conjugate vaccines. We have prepared gold 
18 glyco-nanoparticles  (GNP)  bearing  two  synthetic  carbohydrate  antigens  related  to 
19 serotypes 19F and 14 of Streptococcus pneumoniae and evaluated their immunogenicity 
20 
21 in vivo. 
22 
23 Results:  A  tetrasaccharide  fragment  of  serotype  14  (Tetra-14),  a  trisaccharide 
24 fragment of serotype 19F (Tri-19F), a T-helper peptide, and D-glucose were loaded 
25 onto  GNP  in  different  ratios.  Mice  immunization  showed  that  the  concomitant 
26 
27 presence of Tri-19F and Tetra-14 on the same nanoparticle critically enhanced the titers of 
28 specific IgG antibodies towards type 14 polysaccharide compared to GNP exclusively 
29 
30 displaying  Tetra-14, while no IgG antibodies against type 19F polysaccharide were 
31 elicited. 
32 
33 Conclusion:  This  work  is  a  step  forward  towards  synthetic  nanosystems  combining 
34 carbohydrate  antigens  and  immunogenic  peptides  as  potential  carbohydrate-based 
35 
36 vaccines. 
37 
38 
39 
KEYWORDS:  gold  glyco-nanoparticles;  carbohydrate-based  vaccines;  immunogenicity; 
40 
41 Streptococcus pneumoniae, capsular polysaccharide fragments. 
42 
43 
44 
45 
46 
INTRODUCTION 
47 
48 The possibility to manage microbial infections through nanomedicine is a hot topic in 
49 
50 research.[1] There are several examples demonstrating the potential of nanoparticles- 
51 based  materials  for  fast,  sensitive  and  specific  bacterial  detection,  as  well  as  of  the 
52 incorporation  of  antimicrobial  nanomaterials  in  medical  devices  to  prevent  microbial 
53 
54 adhesion and infection. Some nanomaterials show strong antibacterial properties and the 
55 
56 
57 
58 
59 
60 
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7 development  of  novel  and  tailored  nanotherapeutics  holds  great  promises  to  treat 
8 infectious   diseases.[2]   Moreover,   nanoparticle   engineering   is   offering   significant 
9 
10 contributions to immunology, in particular with regards to the understanding of immune 
11 mechanisms  and  in  vaccine  development.[3]  Nanoparticles  have  been  used  both  as 
12 
13 vaccine carriers and adjuvants in formulations against infectious diseases.[4-6] Repetitive 
14 antigen display and the ability to potentiate immune responses through enhanced antigen 
15 
16 
delivery to the immune system are some key points related to nanotechnology-based 
17 
vaccines.[7] 
18 
19 The  growing  evidence  on  the  role  of  carbohydrates  both  in  innate  immunity[8]  and 
20 adaptive  immunity[9]  has  strengthened  the  interest  in  these  biomolecules.  Although 
21 
22 carbohydrates are usually T cell independent antigens, and thus unable to induce memory 
23 response,  they  can  be  converted  into  potent  immunogens  by  chemical  coupling  to 
24 immunogenic  protein  carriers  (glycoconjugate  vaccines).[10]  Glycoconjugate  vaccines 
25 
26 against a number of diseases, mostly bacterial infections, have been already licensed or 
27 are in their advanced development.[11] However, their development is based on complex 
28 
29 chemical manipulations and time-consuming purification steps, leading to a significant 
30 increase  in  manufacturing  costs.  Furthermore,  there  are  considerable  variations  in 
31 
32 
immunogenicity and safety among various existing carbohydrate-based vaccines against 
33 
microbes, for example, due to the presence of multifarious glycoforms and unselective 
34 
methods used for polysaccharide isolation from natural sources. Therefore, identification, 
35 
36 characterization, and synthesis of key carbohydrate epitopes capable of inducing a 
37 robust antibody response against polysaccharide antigens is a major step in the design of 
38 
39 more efficacious glycoconjugate vaccines.[12] The first semi-synthetic human vaccine was 
40 developed by Bencomo and collaborators against Haemophilus influenzae type b and 
41 based on a synthetic oligosaccharide conjugated to tetanus toxoid as a protein carrier.[13] 
42 
43 The risk associated with protein carrier-induced epitopic suppression[14] have pushed 
44 researchers to seek alternatives to currently employed glycoconjugate vaccines and to 
45 
46 investigate the use of nanotechnology-based approaches to promote the development of 
47 new and more efficient vaccine settings.[15], [16] 
48 
49 The importance of multivalent carbohydrate-protein interactions,[17, 18] for example in the 
50 early  steps  of  host  infection  by  several  bacteria  and  viruses,  makes  glycosylated 
51 
52 nanomaterials attractive models for presenting glycans in a multivalent fashion, which is 
53 abundantly  exploited  in  glycoscience.[19]   Nanomaterials  loaded  with  carbohydrate 
54 
55 antigens have emerged as synthetic vaccine candidates, as they give the possibility to 
56 
57 
58 
59 
60 
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7 tune   the   loading   of   well-defined   carbohydrates   on   different   scaffolds.[20],   [21] 
8 Furthermore,  besides  the  intrinsic  adjuvant  properties  of  many  nanomaterials,  other 
9 
10 structures can be incorporated onto the nanosystems as active mediators to increase 
11 vaccine efficacy, such as cell targeting moieties or Toll-like receptor ligands.[22] Among 
12 
13 multivalent scaffolds, gold nanoparticles hold high potential for their relative inertness, low 
14 toxicity, and easiness  of functionalization especially through thiol-based chemistry.[23] 
15 
16 
Carbohydrates derivatized with thiol-functionalized linkers can be incorporated as ligands 
17 
onto gold nanoparticles.[24] The size and the shape of the resulting “gold glyco- 
18 
nanoparticles” (GNPs) are easily controlled depending on the synthetic methodology, while 
19 
20 the carbohydrate density and presentation on the gold surface can be tuned by inserting 
21 other  thiol-ending  ligands.[24],  [25]  In  addition,  carbohydrate  coating  ensures  water 
22 
23 dispersibility,  stability  and  biocompatibility.  Examples  related  to  the  use  of  GNPs  as 
24 vaccine candidates have been reported, like the GNP constructs containing the tumor 
25 associated Tn antigen,[26, 27] a tetrasaccharide of Streptococcus pneumoniae,[28] or 
26 
27 functionalized with lypopolysaccharide (LPS) to protect against Burkolderia mallei.[29] 
28 
29 Capsular  polysaccharides  (CPS)  of  encapsulated  bacteria are critical  determinants  of 
30 bacterial virulence and have been used in the development of protective vaccines.[30] The 
31 
32 
gram positive bacterium Streptococcus pneumoniae (pneumococcus; Pn) is an important 
33 
causative agent of severe forms of bacterial infectious diseases. Serotypes 19F (Pn19F) 
34 
and 14 (Pn14) are among the major groups responsible for pneumococcal infections and 
35 
36 included  in  the  current  commercial  pneumococcal  conjugate  vaccine.[31]  In  previous 
37 work,[28]  some  of  us  prepared  GNPs  functionalized  with  the  synthetic  branched 
38 
39 tetrasaccharide  repeating  unit  of  the  type  14  pneumococcal  capsular  polysaccharide 
40 (Pn14PS), and the peptide fragment (OVA323-339), serving as a T-helper epitope.[32] 
41 The immunological evaluation of these GNPs demonstrated their ability to elicit specific 
42 
43 and functional IgG antibodies against native Pn14PS, thus promoting uptake and killing of 
44 bacteria Pn14.[28]  
45 47 
48 
Herein, we report on the preparation and immunological evaluation of new types of GNPs 
49 
containing, together with the OVA323-339 T-helper peptide, i) the trisaccharide repeating 
50 
unit of serotype 19F pneumococcal polysaccharide (Pn19FPS), and ii) both serotypes 14 
51 
52 and 19F CPS fragments simultaneously displayed on nanoparticle surface. We sought to 
53 explore the effect of these GNPs, coated with different antigen patterns, on how the 
54 
55 immunological response  
56 
57 
58 
59 
60 
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7 and whether this response is affected by the presence of 
8 both  saccharide  antigens  from  diverse  bacterial  serotypes  loaded  onto  the  same 
9 
10 nanoparticle.The main goal of  this study was to determine whether these GNPs could 
11 induce specific antibodies against both CPSsofpneumococcalserotypes14or19F or to 
12 
13 affect  the immune activity of one of  them. We found that the bi-antigenic GNPs  
14 induced anti-Pn14PS IgG antibodies titers of the same order of magnitude of the currently 
15 
16 
used PCV13 human vaccine. 
17 
MATERIALS & METHODS 
18 
19 Synthesis of the ligands (neoglycoconjugates and T-helper peptide). 
20 
21 In order to prepare our new GNPs as a fully synthetic carbohydrate vaccine candidate, the 
22 selected components (carbohydrate antigens and T-helper peptide) must be derivatized as 
23 
24 thiol-ending ligands in order to be efficiently conjugated to the gold nanocarrier, taking 
25 advantage  of  the  sulfur-gold  high  affinity.  The  thiol-functionalized  19F  trisaccharide  1 
26 
27 (Figure  1)  was  prepared  according  to  the  procedure  previously  described  for  the 
28 preparation of the thiol-functionalized type 14 tetrasaccharide 2,[28] through formation of a 
29 
30 
thiourea  bond between the  3-aminopropyl  glycoside of Tri-19F, compound 3,  and an 
31 
amphiphilic  bifunctional  linker  containing  an  isothiocyanate  group  at  one  end  and  a 
32 
thioacetate at the other end. Glycoside 3 was in turn obtained as an anomeric mixture (α/β 
33 
34 ratio:  2/3,  separable  by  flash  chromatography)  by  glycosylation  of  N-carbobenzyloxy- 
35 protected 3-aminopropanol with the corresponding known trisaccharide 
36 
37 trichloroacetimidate donor[33, 34] followed by hydrogenolysis (90% yield over 2 steps) (a 
38 detailed description of the synthesis is reported in the Supplementary Material). 
39 
40 The D-glucose derivative 4, glycosylated with a five carbon atoms thiol-ending linker, was 
41 prepared as previously described[35] and used as inner component of the GNPs. The 
42 
43 inclusion of  compound 4 into onto the GNPs improves their water  solubility, enables 
44 modulating the loading of the oligosaccharide antigens, and favors the correct exposure of 
45 the  ligands  on  the  organic  shell  of  the  GNPs.  T-Helper  ovalbumin  323-339  peptide 
46 
47 (OVAp), derivatized at the N-terminus with an additional glycine and a mercapto-propionic 
48 acid linker, HS(CH2)2C(O)GISQAVHAAHAEINEAGR, was obtained from GenScript Corp 
49 
50 (Piscataway, NJ, USA). 
51 
52 
53 
Preparation of gold glyco-nanoparticles (GNPs). 
54 
55 
56 
57 
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59 
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7 The  GNPs  were  prepared  through  a  versatile  methodology  developed  by  Penadés 
8 group[36] and based on a modification of the Brust’s procedure.[37] Water-dispersible gold 
9 
10 GNPs of 2 nm (average gold diameter) were obtained by adding a 0.025 M aqueous 
11 solution of tetrachloroauric acid (HAuCl4, 1 eq.) to a 0.012 M methanolic solution of a 
12 
13 mixture of the thiol-derivatized neoglycoconjugates (5 eq. with respect to HAuCl4) in the 
14 desired proportion (see Supplementary Material). The resulting mixture was reduced in 
15 
16 
situ with a freshly prepared 1 M aqueous solution of NaBH4 (27 eq.) and the suspension 
17 
was vigorously shaken for 2 h at 25 °C. The supernatant was removed, the nanoparticles 
18 
were washed with methanol and then dissolved in milliQ water, purified by dialysis (Slide- 
19 
20 A-Lyzer 3.500 MWCO Dialysis Cassette, 9 x 3L water changes) and characterized by 
1
H 
21 NMR spectroscopy, transmission electron microscopy (TEM) and ultraviolet-visible (UV- 
22 
23 Vis) spectroscopy. GNPs produced were well-dispersible and stable in water, could be 
24 freeze-dried and easily re-dispersed in water after thawing. Full details of the synthesis 
25 can be found in the Supplementary Material. 
26 
27 
28 
29 Mice Immunization 
30 
31 
The mouse immunization study was approved by the Animal Care and Use Committee of 
32 
PT. Bimana Indomedical, Bogor, Indonesia. Inbred 6-week-old female BALB/c mice were 
33 
maintained at the Animal Laboratory of PT. Bimana Indomedical, Bogor, Indonesia. Five 
34 
35 mice per group were immunized intradermal with 6.0 µg of GNPs in mixture with 20 µg of 
36 Quil-A®  saponin  adjuvant  (a  gift  from  Dr.  Erik  B.  Lindblad  and  Brenntag  Biosector, 
37 
38 Denmark).[28, 32] A booster of 6.0 µg of GNPs antigen was given on day 35 without 
39 adjuvant.   Blood  samples   were  taken   one   week   after   the  booster   immunization. 
40 Commercially available PCV13 vaccine (13-valent pneumococcal conjugate vaccine, cp 
41 
42 Pfizer, Inc.) was diluted in saline 1:10 (100 µl per mouse)[38] and used as positive control. 
43 PCV13 contains the capsular polysaccharide antigens of S. pneumoniae serotypes 1, 3, 4, 
44 
45 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, individually conjugated to a nontoxic 
46 diphtheria CRM197. Saline (0.9% [wt/vol] NaCl in water) was used as negative control. 
47 
48 
49 
50 Enzyme-linked immunosorbent assay 
51 
52 The  enzyme-linked  immunosorbent  assay  (ELISA)  was  performed  to  measure  the 
53 antibody titers to native Pn14PS and to Pn19FPS at the Eijkman Institute for Molecular 
54 Biology, Jakarta, Indonesia as described previously.[28] 
55 
56 
57 
58 
59 
60 
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7 Briefly, serially diluted sera from immunized animals were incubated for 1 h at 37 °C in 
8 flat-bottom plates, coated with 100 µl of purified Pn14PS or Pn19FPS (5 µg/mL). After 
9 
10 coating,  the  plates  were  blocked  with  3%  gelatin,  then  washed  and  horseradish 
11 peroxidase-conjugated goat anti-mouse IgG was added and incubated for 1 h at 37 °C. 
12 
13 A ready-to-use 3,3′,5,5′-tetramethylbenzidine (TMB) substrate was added to visualize 
14 the amount of bound peroxidase. The reaction was stopped by the addition of 0.5 M 
15 
16 
H2SO4.   Optical   density   (OD)   values   were   obtained   with   a   micro-titer   plate 
17 
spectrophotometer  at  450  nm.  Antibody  titers  were  expressed  as  the  log10   of  the 
18 
dilution giving twice the OD obtained for control mice. 
19 
20 GNP-2 (Tri-19F:Glc:OVAp=45:50:5) and GNP-4 (Tetra-14:Glc:OVAp=45:50:5)-coated 
21 plates  (25  µg/mL)  were  also  used  to  measure  antibody  titers  towards  GNPs 
22 
23 components in the sera of immunized mice as described previously.[39] 
24 Dataanalysis 
25 Independentt-testwasusedtodeterminedifferencesinantibodytiterlevelswithap- 
26 
27 value≤0.05consideredtobestatisticallysignificant. 
28 
29 
30 Other methods 
31 General information about chemicals and techniques, and details of the synthesis of 
32 
33 
compounds 1 and 3, the preparation and characterization of hybrid gold nanoparticles 
34 
GNP-1–4, ELISA assays on compound 3, and determination of IgG subclasses can be 
35 
found in the Supplementary Material 
36 
37 
38 RESULTS 
39 
40 Preparation and characterization of gold glyco-nanoparticles. 
41 GNP-1, GNP-2, GNP-3 and GNP-4 (Figure 2) were prepared by in situ reduction of an 
42 aqueous solution of an Au(III) salt with sodium borohydride in the presence of an excess of 
43 
44 the thiol-ending ligands (Figure 1) in order to assure full coverage of the GNP surface.[36] 
45 This method allows incorporation of ligands in defined proportions on the same gold 
46 
47 nanoparticle,  and  ensures  that  their  molar  ratio  in  solution  is  maintained  on  the 
48 nanoparticle  surface.  Four  systems  based  on  gold  nanoparticles  were  prepared  and 
49 
50 
evaluated in this study: the biantigenic hybrid system GNP-1 coated with the branched 
51 
tetrasaccharide repeating unit of Pn14 [β-D-Galp-(1→4)-β-D-Glcp-(1→6)-[β-D-Galp-(1→4)- 
52 
]-β-D-GlcpNAc-(1→]  (Tetra-14)  and  the  trisaccharide  repeating  unit  of  Pn19F  [β-D- 
53 
54 ManpNAc-(1→4)-α-D-Glcp-(1→2)-α-L-Rhap-(1→]  (Tri-19F)  together  with  D-glucose  and 
55 
56 
57 
58 
59 
60 
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7 OVAp (40:40:15:5 ratio); GNP-2 displaying Tri-19F, D-glucose and OVAp (40:50:5 ratio); 
8 GNP-3 carrying Tri-19F and OVAp (95:5 ratio) but lacking D-glucose; and the system used 
9 
10 in  our  previous  work,  GNP-4  coated  with  Tetra-14,  D-glucose,  and  OVAp  (45:50:5 
11 ratio).[28] 
12 
13 The new GNPs were water-dispersible and stable for several weeks in aqueous solution. 
14 
15 
GNPs showed an exceptionally small core with an average diameter (less than 2 nm), as 
16 
demonstrated  by  TEM  images.  In  addition,  TEM  micrographs  showed  uniform  size 
17 
dispersion of the GNPs and no aggregation. Based on the gold core size and Murray’s 
18 
19 data,[40] an average molecular formula and the corresponding molecular weight were 
20 estimated (Table 1). 
21 
22 UV/Vis spectra gave an indication of the GNPs dimensions:[41] no maximum absorption 
23 band at 520 nm was observed, which further confirmed a GNP size less than 2 nm. An 
24 example for the GNP characterization is provided in Figure 3 for GNP-1. NMR was used to 
25 
26 qualitatively assess the presence of organic components at the gold surface. 
1
H NMR 
27 spectra  of  the  initial  ligand  solution  used  to  prepare  the  GNPs  were  recorded  and 
28 
29 compared  with  data  obtained  from  recovered  supernatants  after  GNP  formation  (i.e. 
30 analyzing the unreacted ligands). In this way, the theoretical molar ratios of the ligands on 
31 
32 
the nanoparticles were confirmed experimentally. 
33 
34 Immunological evaluation 
35 
36 Specific antibodies against Pn14PS, Pn19FPS, and Pn23FPS were measured in the 
37 sera of immunized mice with a series of GNPs using ELISA. Quil-Awasco-delivered 
38 
39 
As  adjuvant during primary, but not upon booster  immunization.  
40 
GNP-1  (Tri-19F/Tetra-14/Glc/OVAp  =  40:40:15:5) induced antibodies 
41 
towards native Pn14PS as coating antigen in higher titers than  ,  GNP-4  (Tetra- 
42 
43 14/Glc/OVAp = 45:50:5; p value = 0.004), and PCV13 (vaccine used as a positive 
44 control antigen,p value=0.347). 
45 
46 We also observed that immunization with GNP-2 (Tri-19F/Glc/OVAp = 45:50:5) and 
47 GNP-3 (Tri-19F/OVAp = 95:5) elicited low antibodies level against Pn14PS (Figure 4). 
48 In addition, we did not detect any specific IgG antibodies against native Pn19FPS and 
49 
50 Pn23FPS (the control polysaccharide coated plate) from the sera of immunized mice 
51 with all GNPs except for the sera of mice immunized with PVC13 vaccine (Figure 4). 
52 
53 IgG  subclasses  against  Pn14PS  antigen  were  also  detected  after  the  booster 
54 immunization had been given at week 5 (Fig. S6, Supplementary Material). GNP-1 
55 
56 
57 
58 
59 
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3 
4 
5 
6 
7 immunization was found to evoke higher levels of anti-Pn14PS IgG-1, IgG-2a, and 
8 IgG2b antibodies subclasses than other GNPs antigens. This data suggests that GNP- 
9 
10 1 ensures a better antigen presentation than other GNPs. 
11 The antibody response to the GNPs was also determined by using GNPs loaded with 
12 
13 Tri-19F  (GNP-2)  or  Tetra-14  (GNP-4)  as  coating  antigens  in  ELISA  assays.  We 
14 observed that the sera of mice immunized with GNP-1, GNP-2, and GNP-3 elicited 
15 
16 
antibodies against GNP-2 (loaded with Tri-19F) in higher titers than the sera of mice 
17 
immunized with PCV13 and GNP-4 (loaded with Tetra-14, figure 5). GNP-4-coated 
18 
plate bound strongly with the sera of mice immunized with GNP-1 (loaded with Tetra- 
19 
20 14/Tri-19F) and GNP-4 (loaded with only Tetra-14), and showed low interaction with 
21 the mice sera of GNP-2 and GNP-3 (both loaded with Tri-19F) as well as the mice sera 
22 
23 of PCV13. 
24 
25 
DISCUSSION 
26 
27 Based on our  previous experience with GNPs carrying the tetrasaccharide (Tetra-14) 
28 repeating  unit  of  Pn14,[28]  all  the  new  GNPs  were  functionalized  with  5%  T-helper 
29 
30 OVA323-339 peptide, which resulted essential to boost an efficient and specific antibody 
31 response. The GNPs  were prepared through a versatile methodology that allows the 
32 
33 
generation of complex globular shaped gold nanoparticles displaying the carbohydrate 
34 
ligands at different densities on the gold surface in a controlled fashion.[35, 42] This 
35 
method requires  that  all  the components  to be coupled  to the  gold  surface,  i.e.  the 
36 
37 saccharide  antigens,  glucose  and  OVA  peptide,  are  functionalized  with  a  thiol  linker 
38 (Figure 1) in order to exploit the affinity of sulfur for gold in the in situ GNPs formation.[43] 
39 
40 The nature and the length of the linker are key factors in controlling the presentation of the 
41 ligands and driving the molecular recognition process.[24] A long bifunctional thiol linker, 
42 23-mercapto-3,6,9,12-tetraoxatricosyl isothiocyanate, had been selected to functionalize 
43 
44 the saccharide pneumococcal antigens Pn14 and Pn19F for the preparation of GNP-1 to 
45 GNP-4. This linker consists of an aliphatic portion of eleven carbon atoms conferring 
46 
47 rigidity to the inner organic shell, thus protecting the gold core, and a hydrophilic portion of 
48 tetraethylenglycol providing flexibility to the glycans on the GNPs. 
49 
50 
The trisaccharide repeating unit (Tri-19F) of Pn19FPS, containing a 3-aminopropyl linker 
51 
at the downstream residue (compound 3, Figure 1), was used as the antigenic fragment of 
52 
Pn19F.  Indeed,  it  was  found  capable  of  inhibiting  the  binding  between  the  19F 
53 
54 polysaccharide and the anti-19F human polyclonal antibody in a classical competitive 
55 
56 
57 
58 
59 
60 
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5 
6 
7 ELISA assay. As shown in Fig. S2 (see Supplementary Material), the two anomers of 
8 saccharide 3, compound 3α and 3β, were tested separately. They were recognized by the 
9 
10 anti-19F antibody, even if with affinity and potency lower than the native polysaccharide. 
11 The  orientation  of  the  aminopropyl  linker  did  not  appear  to  affect  the  affinity  of  the 
12 
13 saccharide for antibody binding (IC50  7.44 x 10
-2  
and 2.61 x 10
-2  
mg/mL for 3α and 3β, 
14 respectively) suggesting the anomeric mixture can be used in the present study without 
15 
16 additional purification steps (see Table S2, Supplementary Material). 
17 GNP-1 bears equimolar amounts of Pn14 tetrasaccharide and Pn19F trisaccharide (1:1 
18 
19 ratio),  together  with  OVAp,  and  D-glucose  to  improve  water  solubility  and  to  enable 
20 modulating the antigen density. A major goal of the synthesis of GNP-1 was to reveal 
21 whether (and how) the distinct pneumococcal antigens simultaneously displayed on the 
22 
23 nanoparticle surface would lead either to the enhancement of their respective biological 
24 activity, or to mutual interference reducing desired protective effects. It would, for example, 
25 
26 be intriguing to determine whether such multiantigenic nanosystem would be able to evoke 
27 an immune response against both serotypes or to enhance the immune activity of one of 
28 them. 
29 
30 Both GNP-2 and GNP-3 contain only the Tri-19F as the pneumococcal saccharide antigen. 
31 While GNP-2, displaying Tri-19F, D-glucose and OVAp was prepared analogous to the 
32 
33 Pn14 based system (GNP-4) that gave the best immunological activation in our previous 
34 work,[28]  GNP-3  lacks  glucose  in  order  to  increase  the  loading  of  the  trisaccharide 
35 
36 antigen. 
37 
38 
ELISA  assays  performed  with  GNP-2  (Tri-19F/Glc/OVAp)  as  antigen-coating 
39 
40 (Figure 5A) showed that only sera collected from mice immunized with GNPs loaded with 
41 Tri-19F (GNP-1, GNP-2, and GNP-3) recognized the antigen. On the other hand, the same 
42 
43 sera were inactive when the native Pn19FPS was coated onto plates. This could be due to 
44 inability of the Pn19F trisaccharide repeating unit on the GNPs to function as epitope in 
45 vivo, although our data demonstrated in vitro inhibitory activity of Tri-19F in a classical 
46 
47 competitive ELISA assay. This could suggest that either a longer saccharide fragment 
48 encompassing  more  than  one  repeating  unit,  which may lead to the formation of a 
49 
50 conformationalepitope, [44] is necessary to induce the activation of the immune system. 
51 Previously,  Safari  et  al.  reported  that  a  linear  trisaccharide  fragment  from  Pn14PS 
52 
53 
conjugated to CRM197 protein carrier did not elicit antibodies against native Pn14PS, 
54 
while the branched tetrasaccharide Tetra-14, corresponding to one structural repeating 
55 
56 
57 
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1 
2 
3 
4 
5 
6 
7 unit of Pn14PS, induced a specific antibody response to Pn14PS, demonstrating that a 
8 small change in the presentation is of great importance for immunoactivity.[32] We further 
9 
10 confirmed these results by showing that sera from mice immunized with GNP-4 (Tetra- 
11 14/Glc/OVAp) were abletorecognize the native Pn14PS in agreement 
12 
13 with our previous data,[28] even if the totalI gGantibodiestiters were lower  
14 than those found with PCV-13 (Figure 4). Strikingly, we found in this study that already the 
15 
16 
di-valent GNP-1 exposing two small saccharide fragments (Tri-19F:Tetra-14:Glc:OVAp) 
17 
was more immunoactive towards native Pn14PS than GNP-4, which contains only Tetra- 
18 
14 saccharide. In addition, the presence of Tri-19F together with Tetra-14 on the same 
19 
20 nanoparticle triggered the generation of specific antibodies towards Pn14PS,  and the 
21 activity was comparable with commercially available PCV13 vaccine. This effect could be 
22 
23 ascribed to a better display of the Tetra-14 saccharide antigen on the GNP-1 surface, 
24 whichpromotesenhancedBcellreceptorcross-linking. 
27 . 
28 Sera from mice immunized with GNP-2 and GNP-3, containing Tri-19F and  D- 
29 
30 glucose, and solely Tri-19F pneumococcal antigen, respectively, showed similar activities 
31 towards  GNP-2  coated  plates  (Figure  5A).  The  higher  antigen  loading  of  GNP-3  in 
32 
33 
comparison to GNP-2 (95% of Tri-19F in GNP-3, 45% in GNP-2) did not lead to higher 
34 
immunoactivity, indicating that the immunogenicity of the GNPs seems not improved by an 
35 
increased loading of the carbohydrate antigen. These results supplement our previous 
36 
37 observations  on  the  importance  of  a  precise  saccharide:OVAp  ratio  on  the  gold 
38 nanoplatform for a robust carbohydrate-directed immune response to occur with GNPs, 
39 
40 and suggests that a payload of saccharide antigen higher than 45% does not correlate 
41 with higher activities. 
42 Unlike proteins, GNPs as carrier system elicit almost no immune response against 
43 
44 themselves. In fact, when GNP-2 (Tri-19F/Glc/OVAp) is used as antigen to coat the ELISA 
45 plate (Figure 5A), mice sera immunized with GNP-4 are unable to recognize the antigen. 
46 
47 This indicates that  no significant antibodies against the additional  components of the 
48 GNPs  (OVAp  T-helper  peptide,  Glc  and  gold)  are  generated.  Further  experimental 
49 
50 
evidence is provided by the results shown in Figure 5B: ELISA plates coated with GNP-4 
51 
(Tetra-14/Glc/OVAp) did not give significant response to sera immunized with GNP-2 (Tri- 
52 
19F/Glc/OVAp) and GNP-3 (Tri-19F/OVAp). 
53 
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4 
5 
6 
7 CONCLUSION & FUTURE PROSPECTIVE 
8 In  conclusion,  we  demonstrated  that  gold  glyco-nanoparticles  coated  with  synthetic 
9 
10 oligosaccharides corresponding to the repeating units of Streptococcus pneumonia CPS 
11 type  14  and  19F  elicit  antibodies  against  carbohydrate  antigens  in  mice  model.  An 
12 
13 unexpected improvement of immunogenicity against the native polysaccharide type 14 
14 was found after immunization with GNPs bearing both types of oligosaccharide epitopes 
15 
16 
(Tri-19F and Tetra-14) with respect to the GNPs that contains only Tetra-14. The presence 
17 
of Tri-19F together with Tetra-14 on the same nanoparticle triggered an immune response 
18 
comparable with commercially available PCV13 vaccine. Although further tests are needed 
19 
20 to elucidate this effect, this work contributes towards the translation of nano-systems 
21 based   on   synthetic   oligosaccharides   and   synthetic   peptides   into   fully   synthetic 
22 
23 glycovaccines. 
24 
25 
26 
27 
28 ETHICAL CONDUCT OF RESEARCH 
29 
30 The mouse immunization study was approved by the Animal Care and Use Committee of 
31 PT. Bimana Indomedical, Bogor, Indonesia. Inbred 6-week-old female BALB/c mice were 
32 
33 
maintained at the Animal Laboratory of PT. Bimana Indomedical, Bogor, Indonesia. 
34 
35 
EXECUTIVE SUMMARY 
36 
37 -  The  preparation  of  an  aminopropyl  synthetic  trisaccharide  related  to  the  capsular 
38 polysaccharide of S. pneumoniae serotype 19F (Tri-19F, [β-D-ManpNAc-(1→4)-α-D-Glcp- 
39 
40 (1→2)-α-L-Rhap-(1→]) has been reported. 
41 - Suitable chemical derivatization of the Tri-19F amino derivative with a bifunctional linker 
42 
43 
containing an amino reactive isothiocianate group at one terminus and a thiol functionality 
44 
at the other terminus was achieved as for an analogous tetrasaccharide related to S. 
45 
pneumoniae serotype 14 (Tetra-14; [β-D-Galp-(1→4)-β-D-Glcp-(1→6)-[β-D-Galp-(1→4)-]-β- 
46 
47 D-GlcpNAc-(1→]). 
48 - Small gold nanoparticles (~2 nm gold diameter) functionalized with different ratios of 
49 
50 neoglycococonjugates Tri-19F and/or Tetra-14 were obtained by modulating the loading 
51 and the presentation of these antigenic carbohydrate fragments through the use of 5- 
52 
53 
(thio)pentyl β-D-glucopyranoside; a thiol-functionalised conjugate of the ovalbumin 323– 
54 
339 peptide (OVA323–339) was also inserted for T-cell activation. 
55 
56 
57 
58 
59 
60 
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1 
2 
3 
4 
5 
6 
7 - Immunogenicity studies in mice showed that the induction of specific IgG antibodies 
8 against Streptococcus pneumoniae type 14 capsular polysaccharide (Pn14PS) can be 
9 
10 modulated by the partner ligands of Tetra-14 in the organic shell of the GNPs. 
11 - The co-presence of Tri-19F together with Tetra-14 in one of the GNPs was critical to elicit 
12 
13 a high level of specific antibody titers against Pn14PS; on the contrary this effect was not 
14 seen towards Pn19FPS. 
15 
16 
- No efficient immune response towards type 19F native polysaccharide was elicited with 
17 
the tested systems. 
18 
19 
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22 Figure  1.  Thiol-ending  derivative  of  the  trisaccharide  related  to  serotype  Pn19F 
23 (compound 1) and its aminopropyl precursor (compound 3); thiol-ending tetrasaccharide 
24 
25 related to serotype Pn14 (compound 2); 5-(thio)pentyl β-D-glucopyranoside (compound 4) 
26 used  as  inner  component  in  the  gold  nanoparticles;  thiol-ending  T-helper  ovalbumin 
27 OVA323-339 peptide (OVAp). 
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25 Figure  2  Gold  glyco-nanoparticles  (GNPs)  prepared  and  used  in  this  work  for  mice 
26 
27 immunization. The GNPs have been functionalized with Pn19F and/or Pn14 saccharide 
28 ligands (see Figure 1) in different ratios by using a glucose derivative as inner and 
29 
30 modulating component. Approximately 5 % of ovalbumin OVA323-339 peptide is always 
31 present. 
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GNP-1 1.2±0.3 79 Tri-19F/Tetra- 
14/Glc/OVAp 
40:40:15:5 
Au79(Tri-19F)15 
(Tetra-14)15(Glc)6 
(OVAp)2 
53.9 
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Au79(Tri-19F)17 
(Glc)19(OVAp)2 
41.8 
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Au79(Tri- 
19F)36(OVAp)2 
55.6 
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Au79(Tetra-14)17 
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Table 1: Main properties of the prepared GNPs. 
9 
10 
11    
12 
13 GNPs 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
Mean 
gold 
core 
(nm)
a
 
Average 
number 
of gold 
atoms
b
 
 
Thiol-ending 
ligands molar 
ratio
c
 
 
Estimated average 
molecular formula 
Average 
molecula 
r weight 
(kDa) 
24 a
Diameter of the gold nanocluster (as measured by transmission electron microscopy). 
25 b
The average number of gold atoms per nanoparticle was calculated from the size of the 26 
gold cluster obtained by transmission electron microscopy. 27 c
Molar ratio of conjugates per nanoparticle was determined by analyzing the mixtures 28 
using NMR before and after nanoparticle formation (Supplementary Material) 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
https://mc04.manuscriptcentral.com/fm-nnm 
 
 
 
 
 
Page 17 of 40 Nanomedicine 
 
 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 ..........     (ftlll) 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
 
 
 
 
 
 
 
 
 
 
 
b)  
t 0      • ' " 1 . 
._  rn•wtr      ) 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
https://mc04.manuscriptcentral.com/fm-nnm 
 
 
 
Nanomedicine Page 18 of 40 
 
 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 Figure  3:  GNP-1  characterization:  a)  TEM  micrograph  in  H2O;  b)  size-distribution 
36 histogram  obtained  by  measuring  around  400  nanoparticles;  c)  UV/Vis  spectrum 
37 (sample  concentration  0.10  mg/ml  in  water);  for  the  characterization  of  the  other 
38 GNPs, see the Supporting Information. 
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25 Figure 4. Total IgG antibodies titers recognizing pneumococcal polysaccharide type 
26 14 (Pn14PS) (blue color), Pn19FPS (red color), and Pn23FPS (green color) as coating 
27 materials. Group of mice (n=5) were immunized with series of GNPs with adjuvant 
28 coadministration  at  the  primary  injection.  Sera  were  collected  one  week  after  the 
29 second booster injection which was given without adjuvant. The GNPs differed in their 
30 molar ratio for the saccharide type: glucose: OVA-peptide (Table 1). PCV13 vaccine 
31 and saline immunization served as positive and negative control respectively. Antibody 
32 titers were expressed as the log10 of the dilution giving twice the absorbance value 
33 corrected by buffer 
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45 
46 Figure 5. Antibodies recognizing GNP-2 (A) and GNP-4 (B). Serial dilutions of pooled 
47 mice sera (ranging from 1:10 to 1:10000) were incubated on ELISA plates coated with 
48 GNP-2 and GNP-4.  The sera  were  obtained from  mice previously immunized with 
49 series of GNPs (Table 1) and control sera were obtained from mice immunized with 
50 PCV13 vaccine (positive control) and saline. Level of antibodies are expressed as 
51 optical density (OD) at 450 nm. 
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1 
2 
3 
SUPPLEMENTARY MATERIAL 
5 
6 
7 Preparation and immunogenicity of gold glyco-nanoparticles as anti- 
8 
9 pneumococcal vaccine model 
10 
11 
12 
13 
14 
15 
16 
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29 
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31 
32 
33 
34 
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38 
39 
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1 
2 
3 GENERAL METHODS 
4 
5 All chemicals were purchased as reagent grade from Sigma–Aldrich, except for 
6 
7 chloroauric acid (Strem Chemicals), and were used without further purification. 
8 
9 Dichloromethane (CH2Cl2) and triethyamine (TEA) were distilled from calcium 
10 
11 
hydride. Methanol (CH3OH) was degassed with Argon before the use to avoid 
12 
oxidation of the thiol ending compounds. Air- and moisture sensitive liquids and 
13 
14 solutions were transferred via oven-dried syringe or stainless steel cannula through 
15 
16 septa. Reactions were monitored by thin-layer chromatography (TLC) on 0.25 mm 
17 
18 pre-coated silica gel plate (Merck 60 F254) with visualization under UV-light (254 nm) 
19 and by staining with 50 % sulfuric acid (aqueous solution) or p-anisaldehyde solution 
20 
21 [anisaldehyde (25 mL), H2SO4 (25 mL), EtOH (450 mL), and CH3COOH (1 mL)] followed 
22 
23 by heating at 200 °C. Size-exclusion column chromatography was performed on 
24 
25 Sephadex LH-20 (GE Healthcare). Flash column chromatography was performed on 
26 silica gel high-purity grade, pore size 60 Å, 230-400 mesh particle size. Organic 
 
28 solvents were removed by rotary evaporation under reduced pressure at 
29 
30 approximately 40°C (water bath). Purified water was obtained from a Simplicity 
31 
32 Ultrapure Water System (Millipore). Nanopure water (18.2 MΩ-cm) was obtained by 
33 
34 
a Thermo Scientific Barnstead NANOpure DIamond Water System. 
35 
All the GNPs were purified by centrifugal filtering with AMICON (10.000 MWCO) 
36 
37 and dialyses carried out using Slide–A-Lyzer dialysis cassette (3500 MWCO). UV/Vis 
38 
39 spectra    were   measured   with   Beckman   Coulter   DU   800   UV/Vis 
40 
41 Spectrophotometer.  To  perform  the  measurement  a  solution  of  GNPs  0,10 
42 mg/ml  in  HPLC  gradient  grade  water  has  been  prepared  and  plastic  cuvettes 
43 
44 with an internal width of 45mm were used. All UV/Vis spectra were subtracted 
45 
46 from blank. 
47 
48 Transmission electron microscopy (TEM) analysis was performed with a Philips 
49 JEOL JEM-2100F microscope, working at 200 kV. A single drop (~2 µL) of a GNP 
51 aqueous solution (ca. 0.05 mg/mL in HPLC gradient grade water) was placed on a 
52 
53 copper grid coated with a carbon film (Electron Microscopy Sciences). The grid was 
54 
55 left to dry in air for several hours at room temperature before carrying on 
56 
57 
58 
59 
60 
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1 
2 
3 the  experiment.  Statistical  determination  of  gold  dimension  was  performed 
4 
5 using Image J program and the average diameter of gold core was correlated to 
6 the number of ligands present on GNP. 
8 
9 1H and 13C NMR spectra were recorded on a Bruker 500 MHz (high resolution) 
10 
11 spectrometer. Chemical shifts (δ) are given in ppm relative to the residual signal 
12 
13 of the solvent  used.  Specifically  7.26  ppm  for CDCl3,  3.31  ppm  for  CD3OH  and 
14 4.79 ppm for D2O in 
1H NMR spectra and 77.0 ppm (central line) for CDCl3  and 
15 
16 49.0 ppm (central line) for CD3OD in 
13C NMR spectra. Coupling constants (J) are 
17 
18 reported   in   Hz.   Splitting   patterns   are   described   by   using   the   following 
19 
20 abbreviations:  br,  broad;  s,  singlet;  d,  doublet;  t,  triplet;  m,  multiplet;  dd, 
21 doublet  of  doublet;  dt,  doublet  of  triplet.  Sugar  residues  are  indicated  as 
 
23 g=glucose,  m=mannosammine,  r=rhamnose. 
24 
25 Mass spectra were recorded with a Thermo Quest Finnigan LCQ™deca ion trap 
26 
27 mass  spectrometer,  or  with  an  Esquire  6000  ESI-Ion  Trap  spectrometer  from 
28 
29 
Bruker Daltonics. High-resolution mass spectra (HRMS) were obtained using the 
30 
MALDI   technique   with   a   4700   Proteomics   Analyzer   (Applied   Biosystems) 
31 
32 operated in MALDI-TOF-TOF configuration. 
33 
34 
35 
36 
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1 
2 
3 Synthesis of thiol-ending ligand. 
4 
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29 Figure S1. Thiol-ending conjugates used for the preparation of GNPs. 
30 
31 
32 
33 
Glucose  conjugate  4  was  prepared  according  to  the  literature.[1]  The  OVA323-339- 
35 peptide OVAp, consisting of ISQAVHAAHAEINEAGR with an additional glycine and 
36 
37 mercaptopropionic   acid   (MPA)   linker   at   the   N-terminus,   was   obtained   from 
38 
39 GenScript Corp (Piscataway, NJ, USA) and a single batch was used throughout the 
40 study. 
42 The thiol-ending conjugate 2 of the tetrasaccharide antigen related to serotype 14, 
43 
44 was synthesized as previously reported.[2] 
45 
46 
47 
48 
49 
50 
Synthesis of the thiol-ending trisaccharide conjugate related to serotype Pn19F 
51 
(Scheme S1) 
52 
53 
54 The  thiol-ending  trisaccharide  conjugate  1  was  prepared  through  a  glycosylation 
55 reaction  between  known  trisaccharide  trichloroacetimidate  donor  5[3,  4]  and  Z- 
56 
57 aminopropanol 6. The reaction, carried out in anhydrous dichloromethane at 0°C, 
58 
59 
60 
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1 
2 
3 was promoted with trimethylsilyl triflate (TMSOTf) in the presence of 4Å powder 
4 
5 molecular  sieves.  Product  7  was  obtained  in  high  yields  (90%)  as  an  alpha/beta 
6 mixture   (4:6),   that   can   be   eventually   separated   by   flash   chromatography. 
8 Subsequently,   compound   7   was   submitted   to   hydrogenolysis   with   palladium 
9 
10 hydroxide  on activated charcoal  in a mixture  of ethyl acetate/methanol/water  as 
11 
12 the solvent in the presence of an amount (1 eq.) of aq. HCl 0.1 M. The deprotected 
13 
14 trisaccharide  derivative  3,  isolated  as  the  chloride  salt,  was  coupled  with  23- 
15 mercapto-3,6,9,12-tetraoxatricosyl isothiocyanate linker 8 in a 
16 
17 water/isopropanol/acetonitrile   mixture   and   in   the   presence   of   triethylamine, 
18 
19 following a previously described procedure.[2] After deprotection of the thioacetyl 
20 
21 group,  the  trisaccharide  conjugate  1  was  obtained  as  a  mixture  of  disulfide  and 
22 thiol,  which  could  be  used  for  the  preparation  of  the  GNPs  under  reductive 
23 
24 conditions (Scheme S1). 
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41 
Scheme S1: a) TMSOTf, m.s. 4Å, dry CH2Cl2, 0°C, 90%; b) Pd(OH)2, H2, AcOEt/CH3OH/H2O 1:1:1, 
42 
HCl 0.1M, rt, quant.; c) TEA 0.05M, H2O/iPrOH/CH3CN 1:1:1, rt, 75%; d) CH3ONa, CH3OH, rt, 
43 
90%. 
44 
45 
46 N-(benzyloxycarbonyl)-3-amminopropyl    (2-acetamido-3-O-benzyl-4,6-O-benzylidene 
47 
48 -2-deoxy-β-D-mannopyranosyl)-(1→4)-(2,3,6-tri-O-benzyl-α-D-glucopyranosyl)- 
49 
50 (1→2)-3,4-di-O-benzyl-L-rhamnopyranoside  7 
51 
52 Compound   5    (90    mg,   0.07    mmol,   1    eq.)    and    N-(benzyloxycarbonyl)-3- 
53 
54 amminopropyl 6 (58 mg, 0.28 mmol, 4 eq.) were dissolved in dry CH2Cl2 (1.5 ml, 
55 0.05M)  and  activated  powder  molecular  sieves  4  Å  (50  mg)  were  added.  The 
56 
57 suspension  was  left  stirring  under  Ar  atmosphere  at room  temperature  for 15 
58 
59 
60 
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1 
2 
3 minutes, then it  was  cooled to  0  °C  and  TMSOTf  0.1  M in dry CH2Cl2  (140  µl, 
4 
5 0.014  mmol,  0.2  eq.)  was  added.  After  15  minutes,  the  reaction  mixture  was 
6 
7 
neutralized  with  TEA,  filtered  over  a  Celite  pad  and  the  solvent  evaporated 
8 
under reduced pressure. Purification of the crude through flash 
9 
10 chromatography   (Hexane/Ethyl   Acetate   6:4)   afforded   compound   7   (85   mg, 
11 
12 0.063  mmol,  90%  yield,  white  foam)  as  an  anomeric  mixture  (α/β ratio:  2/3). 
13 
14 This   elution   system   allows   the   separation   of   the   two   anomers   by   flash- 
15 chromatography   even   if   a   complete   separation   of   the   anomeric   mixture 
 
17 requires  repetitive  columns:  the  α-anomer  is  less  polar  and  is  eluted  firstly, 
18 
19 while  the  β-anomer  is  recovered  secondly.  At  this  stage  were  recovered  the 
20 
21 necessary amount of pure 7-α and 7-β in order to obtain, after hydrogenolysis, 
22 
23 3-α and 3-β for Elisa assays (Figure S2). 
24 
25 1H-NMR (CDCl3): δ=1.38 (d, 1.2H, J6r,5r=6.2 Hz, CH3α), 1.42 (d, 1.8H, J6r,5r=6.2 Hz, 
26 
27 CH3β), 1.62-1.80 (m, 2H, CH2), 1.76 (s,  1.2H, CH3COα),  1.77 (s, 1.8H,  CH3COβ), 
28 
29 3.03-3.10  (m,  1H,  H-5m),  3.21-5.15  (m,  35.4H,  OCH2CH2CH2N,  OCH2CH2CH2N, 
30 
0.4H-1gα, H-2g, H-3g, H-4g, H-5g, 2H-6g, H-1r, H-2r, H-3r, H-4r, H-5r, H-1m, H- 
32 2m, H-3m, H-4m, 2H-6m, 7CH2Ph), 5.48 (s, 1H, CHPh), 5.53 (br d, 1H, J=10.9 Hz, 
33 
34 NH), 5.63 (d, 0.6H, J=3.6 Hz, H-1gβ), 7.19-7.52 (m, 40H, 8Ph); 
35 
36 
13C-NMR  (CD3Cl):  δ=17.9  (CH3β),  18.0  (CH3α),  23.1  (CH3COβ),  23.3  (CH3COα), 
37 
38 29.6 (CH2α), 29.8 (CH2β), 38.0 (CH2Nβ), 38.8 (CH2Nα), 50.5 (C2m), 65.4 (OCH2), 
39 
40 
66.5  (CH2Ph-cbzβ),  66.7  (CH2Ph-cbzα),  67.1  (C5mα),  67.4  (C5mβ),  67.9  (C6gα), 
41 68.2  (C6gβ),  68.4  (C5rα),  68.6  (C5rβ),  69.2  (C5gβ),  69.8  (C5gα),  70.9  (CH2Ph), 
42 
43 71.2  (CH2Ph),  71.9  (CH2Ph),  72.1  (CH2Ph),  72.7  (CH2Ph),  73.4  (CH2Ph),  74.2 
44 
45 (CH2Ph), 74.7  (CH2Ph), 75.0 (C2r), 75.3 (CH2Ph), 75.5  (C4gα),  75.7  (C4gβ), 75.9 
46 
47 (C3m),  78.5  (C4m),  79.0  (C3rα),  79.2  (C3rβ),  79.7  (C2gα),  79.8  (C2gβ),  80.0 
48 
49 (C4rβ),  80.1  (C4rα),  80.3  (C3gβ),  80.4  (C3gα),  96.8  (C1gβ),  96.9  (C1gα),  97.5 
50 (C1r), 99.6  (C1m), 101.6  (CHPh  benzilidene),  126.1, 126.3,  126.4, 126.5, 126.6, 
51 
52 127.2-127.9 (16C), 128.0-128.6 (18C), 128.9, 129.0, 129.7, 134.4, 136.6 (2C Cbz 
53 
54 α and  β), 134.3, 137.4, 137.6  (3C),  137.7  (2C), 137.8, 138.1 (3C), 138.2, 138.3 
55 
56 (2C),   138.4   (3C),   138.5   (3C),   138.7   (2C),   139.5,   139.6   (2C),   139.7,   156.3 
57 
(OCONH), 170.4 (CONHAc). 
59 
60 
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1 
2 
3 ESI-MS (CH3OH, positive-ion mode): m/z 1371.5  (100%)  [M+Na]
+, 1372.5 (90%) 
4 
5 [M+Na+1]
+, Calcd for C80H88N2O17, m/z 1348.61 [M]. 
6 
7 
8 3-Aminopropyl 2-acetamido-2-deoxy-β -D-mannopyranosyl-(1→4)-α-D- 
9 
10 glucopyranosyl-(1→2)- L-rhamnopyranoside 3 
11 
12 The  protected  trisaccharide  7  (39  mg,  0.029  mmol,  1  eq.)  was  dissolved  in  a 
13 
14 1:1:1  mixture  of  AcOEt/CH3OH/aq.HCl  0.1M  (1  ml,  0.03M)  and  submitted  to 
15 
16 hydrogenolysis  at  atmospheric  pressure  with  palladium  hydroxide  on  activated 
17 charcoal  (39  mg)  as  the  catalyst.  After  48  hours,  the  mixture  was  filtrated  to 
18 
19 remove the catalyst and the filtrate was concentrated under reduced pressure. 
20 
21 Product 3 was isolated as the chloride salt (17 mg, quant.) as a white solid after 
22 
23 freeze drying. 
24 
25 1H-NMR (D2O): δ=1.32 (d, 1.2H, J6r,5r=6.2 Hz, CH3α), 1.34 (d, 1.8H, J6r,5r=5.8 Hz, 
26 
27 CH3β), 1.97-2.03 (m, 2H, CH2), 2.09 (s, 3H, CH3CO), 3.15 (t, 2H, J=7.2 Hz, CH2N), 
28 
29 3.40-4.05 (m, 15.4H, H-2g, H-3g, H-4g, 2H-6g, 0.4H-2rα, H-3r, H-4r, H-5r, H-3m, 
30 
H-4m, H-5m, 2H-6m, OCH2), 4.06-4.08  (m, 0.4H,  H-5gα), 4.10  (d, 0.6H, J2,3=3.1 
32 Hz,  H-2rβ),  4.18  (dt,  0.6H,  J5,6=2.7  Hz,  J5,6’=10.2  Hz,  H-5gβ),  4.57  (br  d,  1H, 
33 
34 J2,3=4.4 Hz, H-2m), 4.74 (s, 0.6H, H-1rβ), 4.91 (br s, H-1m), 4.93 (d, 0.4H, J1,2=1.2 
35 
36 Hz, H-1rα), 5.01 (d, 0.4H, J1,2=3.8 Hz, H-1gα); 5.15 (d, 0.6H, J=3.8 Hz, H-1gβ); 
37 
38 
13C-NMR  (D2O):  δ=16.5  (CH3α),  16.6  (CH3β),  22.0  (CH3CO),  26.6  (CH2α),  26.8 
39 
40 (CH2β), 37.5 (CH2Nα), 37.6 (CH2Nβ), 53.3 (C2m), 59.6 (C6gα), 59.8 (C6gβ), 60.4 
41 (C3m),  65.1  (OCH  α),  66.6  (C4m),  67.3  (OCH β),  68.9,  69.6,  70.2  (C5gβ),  70.3 
42 
43 (C5gα),  71.1,  71.2,  71.5  (C2gβ), 71.8  (C2gα),  71.9  (C5rα and  C5rβ),  72.0 (C3rα 
44 
45 and  C3rβ),  72.5  (C4rα),  76.3  (C5m),  76.5  (C6m),  77.9  (C2rβ),  78.6  (C4gα and 
46 
47 C4gβ), 97.2  (C1rα),  97.5  (C1gα), 99.3  (C1mα),  99.4  (C1mβ),  99.8  (C1gβ), 100.4 
48 
49 (C1rβ), 175.4 (CONHAc); 
50 
51 
ESI-MS   (CH3OH,   positive-ion   mode):   m/z   587.1   (95%)   [M+1] ,   609.5   (50%) 
52 [M+Na]+, Calcd for C23H42N2O15, m/z 586.58 [M]. 
53 
54 
55 
Synthesis of S-acetylated trisaccharide conjugate 9 
57 
58 
59 
60 
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1 
2 
3 To a solution of 3-aminopropyl trisaccharide 3 (3.91 mg, 6.27 μmol, 1.0 equiv.) 
4 
5 in  H2O:iPrOH:CH3CN  (1:1:1,  v/v/v,  0.6  mL)  a  solution  of  23-mercapto-3,6,9,12- 
6 tetraoxatricosyl  isothiocyanate  linker  8  (5.82  mg,  12.55  μmol,  2.0  equiv.)  in 
8 H2O:iPrOH:CH3CN (1:1:1, v/v/v, 0.6 mL) was added and the pH was set to basic 
9 
10 by  addition  of  triethylamine  0.05  M  in  H2O:iPrOH:CH3CN,  1:1:1  (188  μL,  9.41 
11 
12 μmol,  1.5  equiv.).  The  mixture  was  stirred  at  room  temperature  for  24  h  and 
13 
14 then the solvent was evaporated. The crude material was kept in high vacuum 
15 to remove the residual triethylamine and then triturated with Et2O (3 × 2ml) in 
16 
17 order to  get rid of the  excess of the linker. The crude was further purified by 
18 
19 Sephadex  LH-20  chromatography  using  as eluent  CH3OH/H2O  9:1  to afford the 
20 
21 trisaccharide conjugate 9 as a white solid (4.95 mg, 4.71 μmol, 75%). 
22 
23 
1H-NMR   (CD3OD):   δ=1.27-1.38   (m,   17H,   CH3,   7CH2),   1.53-1.60   (m,   4H, 
24 
25 CH2CH2SAc,  OCH2CH2(CH2)9SAc),  1.81-1.91  (m,  2H,  OCH2CH2CH2N),  2.02  (s,  3H, 
26 NHAc), 2.30 (s, 3H, SAc), 2.86 (t, 2H, J=7.3 Hz, CH  SAc), 3.27-3.93 (m, 35.4H, H- 
27 
28 2g,  H-3g,  H-4g,  2H-6g,  0.4H-2rα,  H-3r,  H-4r,  H-5r,  H-3m,  H-4m,  H-5m,  2H-6m, 
29 
30 9CH2O,  2CH2N),  4.00  (d,  0.6H,  J1,2=3.8  Hz,  H-2rβ),  4.04-4.07  (m,  0.4H,  H-5gα), 
31 
32 4.13-4.17 (m, 0.6H, H-5gβ), 4.50 (br d, 1H, J=4.1 Hz, H-2m),4.61 (s, 0.6H, H-1rβ), 
33 
34 4.78 (s, 1H, H-1m), 4.83 (d,0.4H, J1,2=0.9 Hz, H-1rα), 4.92 (d, 0.4H, J1,2=3.8 Hz, H- 
35 
36 1gα), 5.11 (d, 0.6H, J1,2=3.8 Hz, H-1gβ); 
37 13C-NMR (CD3OD): δ=18.0 (2CH3) 22.7 (2CH3CO), 27.1 (CH2), 29.8, 29.9 (CH3CO), 
38 
39 30.2 (SAc), 30.5 (2CH2), 30.6 (2CH2), 30.7 (2CH2), 37.5 (CH2N), 47.8, 54.9 (C2mα 
40 
41 and C2mβ), 61.3, 61.4, 61.9, 66.3, 68.2 (2C), 70.2, 70.7, 70.8, 71.1, 71.3, 71.5, 
42 
43 71.6,  71.7,  71.8,  71.9,  72.4,  73.2,  73.5,  73.7,  73.8,  74.0  (2C),  74.1,  74.2,  74.5 
44 
45 (2C), 78.6, 78.7,  79.9, 80.1, 80.3, 99.2  (C1rα),  99.6  (C1gα),  100.9  (C1m), 101.8 
46 (C1gβ), 102.1(C1rβ), 174.7 (NCOCH3), 190.9 (S=C) 197.6 (SCOCH3); 
47 
48 TOF MS ESI (CH3OH, positive-ion mode): m/z 1072.7 (100%) [M+Na]
+, Calcd for 
49 
50 C45H83N3O20S2, m/z 1049.50 [M]. 
51 
52 
53 Synthesis of the thiol-ending trisaccharide 1 
54 
55 To a solution of S-protected trisaccharide 9 (4.95 mg, 4.71 μmol, 1.0 equiv.) in 
56 
57 CH3OH (500 µL, 0.01M) solid CH3ONa (0.500 mg, 9.42 µmol, 2.0 eq.) was added. 
58 
59 
60 
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1 
2 
3 The mixture was stirred at room temperature for 4 hours under Ar atmosphere 
4 
5 until   
1H   NMR   check   analysis   attested   the   complete   disappearance   of   the 
6 starting  material.  The  solvent  was  evaporated  and  the  crude  material  was 
8 purified by Sephadex LH-20 chromatography using as eluent CH3OH/H2O 9:1 to 
9 
10 afford the trisaccharide conjugate product 1 (7:3 mixture of disulfide and thiol) 
11 
12 as a white solid after lyophilisation (4.32 mg, 4.28 μmol, 90%). 
13 
14 1H-NMR  (CD3OD):  δ=1.26-1.44  (m,  17H,  CH3,  7CH2),  1.53-1.62  (m,  2.6H,  0.6 
15 
16 CH2CH2SH,   2   OCH2CH2),   1.65-1.71   (m,   1.4H,   CH2CH2SS),   1.72-1.82   (m,   2H, 
17 
18 OCH2CH2CH2N), 2.03 (s, 3H, NHAc), 2.49 (t, 0.6H, J=7.3 Hz, CH2SH) 2.69 (t, 1.4H, 
19 J=7.3 Hz, CH2SS), 3.25-4.17 (m, 37H, H-2g, H-3g, H-4g, H-5g, 2H-6g, H-2r, H-3r, 
20 
21 H-4r, H-5r, H-3m, H-4m, H-5m, 2H-6m, 9CH2O, 2CH2N), 4.50 (d, 1H, J = 3.7 Hz, H- 
22 
23 2m), 4.78 (s, 1H, H-1m), 4.81 (s, 1H, H-1r), 4.91 (H-1g), 5.11 (d, 0.6H, J=3.8 Hz, 
24 
25 H-1gβ); 
13C-NMR  (CD3OD):  δ=18.0  (CH3)  22.7  (CH3CON),  27.2  (CH2),  29.4,  30.3,  30.6, 
28 30.7, 31.3, 39.8, 40.9, 54.9 (C2m), 61.4, 61.9, 66.3, 68.2, 71.1, 71.2, 71.6, 71.9, 
29 
30 72.0,  72.4,  74.1,  74.5,  78.6,  79.8,  80.1,  80.2,  99.2  (C1rα),  99.5  (C1gα),  100.6 
31 
32 (C1m), 101.4 (C1gβ), 101.9 (C1rβ), 174.7 (NCOCH3); 
33 
34 TOF  MS  ESI  (CH3OH,  positive-ion  mode):  m/z=1030.48  (100%)  [M+Na
+],  Calcd 
35 
for C43H81N3O19S2, m/z=1007.49 [M]. 
37 
38 
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1 
2 
3 Competitive ELISA assay 
4 
5 96-Well flat-bottomed plates were incubated overnight at 4–8 °C with a mixture of 
6 
7 S.  pneumoniae  19FPS  (Sanofi-Aventis,  France)  (1  mg/mL)  and  methylated  human 
8 
9 serum  albumin  (1  mg/mL).  A  solution  of  foetal  calf  serum  (5%)  in  phosphate- 
10 buffered  saline  supplemented  with  Brij-35  (0.1%)  and  sodium  azide  (0.05%)  was 
12 applied  to  the  plates  for  blocking  of  nonspecific  binding  sites.  The  plates  were 
13 
14 incubated overnight at  4–8 °C with a solution (1:200) of rabbit anti-19F, used as 
15 
16 reference serum  (Statens  Serum  Institut,  Artillerivej, Denmark).  When  alpha-  and 
17 
18 beta- aminopropyl glycosides, 3-α and 3-β, were tested, they were added to each 
19 well immediately before the addition of the reference serum. The plates were then 
20 
21 incubated with alkaline phosphatase conjugate goat anti-rabbit IgG (Sigma- Aldrich, 
22 
23 Milan,   Italy),   stained   with   p-nitrophenylphosphate,   and   the   absorbance   was 
24 
25 measured  at  405  nm  with  an  Ultramark  microplate  reader  (Bio-Rad  Laboratories 
26 S.r.l., Milan, Italy). Control experiments to verify unspecific binding were performed 
28 by coating the ELISA plates with colominic  acid from Escherichia coli.  Results are 
29 
30 expressed as means ± SEM of at least three experiments run in triplicate. Data were 
31 
32 fitted   as   sigmoidal   concentration-response   curves   and   analyzed   with   a   four- 
33 
34 parameter  logistic  equation  by  using  the  software  Origin  version  6.0  (Microcal 
35 Software, Northampton, MA, USA). The IC value was the concentration (mg/mL) 
36 
37 of  synthetic  compound  that  inhibits  the  binding  of  the  native  Pn19F  CPS  to  the 
38 
39 specific anti-Pn19F antibody by 50% and it was calculated using the same software. 
40 
41 
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24 Figure S2 Concentration–response curves of saccharides 3-α, 3-β and 19FPS on the 
25 inhibition of the binding between the 19F polysaccharide, coated onto the plates, 
27 and the anti-19F human polyclonal antibody were evaluated by a competitive ELISA 
28 method. Values are means of at least four experiments run in triplicate. 
29 
30 
31 
32 
33 
34 Table S1. Results of the competitive Elisa assays 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 a 
51 The maximum inhibition elicited by each compound at 1 mg/ml. 
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1 
2 
3 Preparation and characterization of the glyconanoparticles 
4 
5 
6 General protocol for the preparation of the GNPs 
7 
8 A  methanolic  solution  0.012  M  of  thiol-ending  conjugates  (5  eq.),  i.e.  the 
9 
10 saccharide  antigens  Pn19F  1  and  Pn14  2,  glucose  4  and  OVAp,  in  the  desired 
11 proportion  was  prepared.  To  this  mixture,  a  solution  of  tetrachloroauric  acid 
13 HAuCl4  in  water (0.025  M, 1  eq.)  was added, followed by  the  addition  in  four 
14 
15 portions under vigorous shaking of an excess of sodium borohydride  NaBH4  as 
16 
17 reductive agent (1 M in H2O, 27 eq.). The black suspension formed was shaken 
18 
19 for 2 hours at room temperature after which the supernatant was removed by 
20 centrifugal filtering with AMICON 10.000 MWCO (5 min, 10.000 rpm, 10 times). 
21 
22 The  dark  concentrated  solute  was  diluted  with the  minimum  volume  of  water 
23 
24 and further purified by dialysis with Slide-A-Lyzer 3.500 MWCO Dialisys Cassette 
25 
26 placed  in  a  2  L  beaker  full  of  NANOPURE  water  under  gentle  stirring.  After 
27 changing the water for nine times in three days, the dark solution was freeze- 
28 
29 dried to give the GNPs as a dark solid, which can be stored at 4°C for months 
30 
31 and redissolved in water prior to use. 
32 
33 The ratio of the ligands on the nanocluster surface was assessed by comparison of 
34 
35 the proton nuclear magnetic resonance (1H NMR) spectra of the initial solution used 
36 
37 to prepare the GNPs, containing the thiolated ligands in the desired ratios, and of 
38 
39 
the  recovered  supernatant  solution  containing  the  unreacted  ligands  after  GNPs 
40 
formation.  Spectra  were  recorded  and  compared  to  confirm  the  expected  molar 
41 
42 ratio  of  the  components  attached  on the  gold  surface  of  the  prepared  GNPs.  In 
43 
44 particular, the  ratio  of the  ligands in  the  GNPs  was  evaluated by  integrating  the 
45 
46 signals of the anomeric protons of the glucopyranosyl unit or of the H-2 proton of 
47 the  mannopyranosyl  unit  of  trisaccharide  1  related  to  Pn19F  antigen,  the  4 
48 
49 anomeric protons of tetrasaccharide 2 related to Pn14 which collapse in an unique 
50 
51 signal, the anomeric proton of glucose 4 and the methyl groups of isoleucine and 
52 
53 valine of OVA323–339 peptide conjugate. 
54 The 
1H NMR spectra of the GNPs showed the characteristic signals of the organic 
 
56 components confirming their presence on the gold surface, even if the peaks are 
57 
58 broader than those of the corresponding free ligands. 
59 
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1 
2 
3 GNP-1 (Pn19F/Pn14/Glc/OVA 40:40:15:5) 
4 
5 A mixture of compound 1 (1.30 mg, 
6 
7 1.29 µmol, 8 eq.), compound 2 (1.53 
8 
9 mg,  1.29  µmol,  8  eq.),  β-D-glucose 
10 
11 conjugate  4  (0.15  mg,  0.52  µmol,  3 
12 eq.), and OVAp (0.33 mg, 0.17 µmol, 
14 1  eq.)  in  CH3OH  (273  µl,  0.012M) 
15 
16 was prepared. 
17 
18 HAuCl4   (26.2  µl,  0.65  µmol,  0.025M  in  H2O,  1  eq.)  and  sodium  borohydride 
19 
20 NaBH4  (17.7 µl, 17.7 µmol, 1M in H2O, 27 eq.) were added to afford 770 µg of 
21 
22 
GNP-1 after the work-up and freeze drying. 
23 
24 TEM: average diameter 1.2±0.3 nm (for 534 GNPs); 
25 
26 Average molecular formula estimated based on the size of the cluster obtained 
27 from TEM micrographs: 
28 Au79  (C43H80N3O19S2)15(C49H90N3O25S2)15(C11H21O6S)6  (C79H126N27O27S)2 ~53.9 KDa; 
29 
30 UV/Vis (H2O, c=0.10 mg/mL): surface plasmon band not observed; 
31 
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1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
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19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 Figure  S3:  (a)  TEM  micrographs  and  (b)  histograms  of  size  distribution,  (c) 
52 UV/Vis  adsorption  spectrum  of  gold  GNP-1.  (d)  
1H  NMR  spectrum  (500MHz, 
53 CD3OD:D2O 5:1) of the mixture used to prepare GNP and (e) 
1H NMR spectrum 
54 (500MHz,  D2O)  of  GNP-1  obtained.  Integration  of  selected  signals  shows  that 
55 the  ratio  between,  trisaccharide  2,  tetrasaccaride  3,  glucose  conjugate  4  and 
57 OVAp is about 40:40:15:5. 
58 
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1 
2 
3 GNP-2 (Pn19F/Glc/OVA 45:50:5) 
4 
5 A mixture of thiol-ending Pn19F 
6 
7 trisaccharide 1 (0.96 mg, 0.95 µmol, 9 
8 
9 eq.),   β-D-glucose   conjugate   4   (0.30 
10 
11 mg,  1.05  µmol,  10  eq.),  and  OVAp 
12 
13 
(0.20 mg, 0.105 µmol, 1 eq.) in CH3OH 
14 (175 µl, 0.012M) was prepared. 
15 
16 HAuCl4   (16.8  µl,  0.42  µmol,  0.025M  in  H2O,  1eq.)  and  sodium  borohydride 
17 
18 NaBH4 (11.4 µl, 11.38 µmol, 1M in H2O, 27 eq.) were added to afford 378 µg of 
19 
20 GNP-2 after the work-up and freeze drying. 
21 
22 TEM: average gold diameter 1.2±0.3 nm (for 309 GNPs); 
23 
24 Average molecular formula estimated based on the size of the cluster obtained 
25 from TEM micrographs: 
26 
27 Au79(C43H80N3O19S2)17(C11H21O6S)19(C79H126N27O27S)2   ~41.8  KDa; 
28 UV/Vis (H2O, c=0.10 mg/mL): surface plasmon band not observed; 
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23 
24 
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26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 Figure S4 (a) TEM micrographs and (b) histograms of size distribution, (c) UV/Vis 
54 adsorption spectrum of gold GNP-2. (d) 
1H NMR spectrum (500MHz, CD3OD:D2O 
55 
5:1)  of  the  mixture  used  to  prepare  GNP  and (e)  1H  NMR  spectrum  (500MHz, 
56 D2O)  of  GNP-2  obtained.  Integration  of  selected  signals  shows  that  the  ratio 
57 between trisaccharide 2, glucose conjugate 4 and OVAp is about 45:50:5. 
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1 
2 
3 GNP-3(Pn19F/OVA  95:5) 
4 
5 A mixture of thiol-ending Pn19F 
6 
7 trisaccharide  1  (1.4  mg,  1.39  µmol,  19 
8 
9 eq.)  and  OVAp  (0.14  mg,  0.07  µmol,  1 
10 
11 eq.)   in   CH3OH   (122   µl,   0.012M)   was 
12 prepared. 
 
14 HAuCl4  (11.7 µl, 029 µmol, 0.025M in H2O, 1eq.) and sodium borohydride NaBH4 
15 
16 (7.9  µl,  7.9  µmol, 1M  in  H2O, 27  eq.)  were  added  to  afford  336  µg  of  GNP-3 
17 
18 after the work-up and freeze drying. 
19 
20 TEM: average diameter 1.2±0.3 nm (for 703 GNPs); 
21 
22 Average molecular formula estimated based on the size of the cluster obtained 
23 
24 from TEM micrographs: 
25 Au79(C43H80N3O19S2)36(C79H126N27O27S)2  ~55.6  KDa; 
26 UV/Vis (H  O, c=0.10 mg/mL): surface plasmon band not observed; 
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34 
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45 
46 
47 
48 
49 
50 
51 
52 
53 Figure  S5:  (a)  TEM  micrographs  and  (b)  histograms  of  size  distribution,  (c) 
54 UV/Vis  adsorption  spectrum  of  gold  GNP-3.  (d)  
1H  NMR  spectrum  (500MHz, 
55 
CD3OD:D2O 5:1) of the mixture used to prepare GNP and (e) 
1H NMR spectrum 
56 (500MHz,  D2O)  of  GNP-3  obtained.  Integration  of  selected  signals  shows  that 
57 the ratio between trisaccharide 2 and OVAp is about 95:5. 
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21 
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23 
24 
25 
26 
27 
28 
29 
30 Figure   S6.   Anti-Pn14PS   IgG   antibodies   subclass   distribution.   Mice   sera   were 
31 collected after the first booster immunization. ELISA was performed to measure the 
32 anti-Pn14PS IgG antibodies subclass distribution: IgG1 (A), IgG2a (B), IgG2b (C), and 
33 
34 IgG3 (D). 
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